Sekiguchi Naohiro, Takezako Naoki, Nagata Akihisa, Wagatsuma Miyuki, Noto Satoshi, Yamada Kazuaki, Miwa Akiyoshi
Hematology Division, National Hospital Organization Disaster Medical Center, Japan.
Intern Med. 2011;50(21):2653-7. doi: 10.2169/internalmedicine.50.5977. Epub 2011 Nov 1.
Immunoglobulin D (IgD) myeloma is a rare subtype and it is widely accepted as an aggressive disease. Here, we report a 66-year-old woman with IgD myeloma who had anemia, lumbago, multiple osteolytic lesions and hypercalcemia. The patient refused a blood transfusion because of her beliefs, so we administered bortezomib and dexamethasone (BD) after high-dose dexamethasone therapy. Marked improvement of anemia and elevated serum alkaline phosphatase levels was recognized. After 5 cycles of BD therapy, the patient achieved a stringent complete response according to International Myeloma Working Group Response Criteria. BD therapy might be a feasible and useful treatment option for IgD myeloma.
免疫球蛋白D（IgD）骨髓瘤是一种罕见的亚型，被广泛认为是一种侵袭性疾病。在此，我们报告一名66岁患有IgD骨髓瘤的女性，她有贫血、腰痛、多发溶骨性病变和高钙血症。由于患者的信仰，她拒绝输血，因此在大剂量地塞米松治疗后，我们给予硼替佐米和地塞米松（BD）治疗。贫血得到明显改善，血清碱性磷酸酶水平升高。经过5个周期的BD治疗，根据国际骨髓瘤工作组反应标准，该患者达到了严格完全缓解。BD治疗可能是IgD骨髓瘤一种可行且有用的治疗选择。
